Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07532603

A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with lichen planopilaris

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Lichen Planopilaris Lichen Planus Lichenoid Eruptions Skin Diseases Skin Diseases, Papulosquamous Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Clinical Trial Site, Adelaide, Australia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years
  • Scalp biopsy consistent with LPP
  • Active and symptomatic LPP at screening and baseline-
  • Weight > 40 kg to < 130 kg with BMI ≤ 45 kg/m2

Exclusion criteria

  • History of: Lymphoproliferative disorder; Active malignancy; History of cancer within 5 years prior to baseline (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid cancer).
  • High risk of thrombosis or cardiovascular disease
  • High risk of herpes zoster
  • Active or recent infection

Treatment and study plan

Oral Brepocitinib

Drug

Oral

Placebo

Drug

Oral

Primary outcomes

  1. Proportion of participants achieving IGA score 0/1 and ≥ 2-step reduction from baseline at Week 24

    Time frame: Week 24

Secondary outcomes

  1. Change from baseline in LPP symptom numerical rating scale scores at Week 24

    Time frame: Week 24

Study contacts

Contact information is provided by the study sponsor or research team.

Clinical Trial Administrator

CONTACT

[email protected]

(212) 634-9743

Sponsors and collaborators

Lead sponsor

Priovant Therapeutics, Inc.

Industry

Registry information

Official study title

A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Lichen Planopilaris

Acronym: ALPINE

Important dates

Study start
2026
Primary completion
2028
Study completion
2029
First posted
Apr 16, 2026
Registry last updated
Jul 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.